DCPG

In today's article, we are going to delve into the fascinating world of DCPG. Whether you are an expert on the subject or are looking for information for the first time, this article is designed to provide you with a broad overview of DCPG. We will explore its origins, its impact on today's society, and take a look at its future. No matter what your level of knowledge about DCPG is, we hope this article is an interesting and enriching read for all our readers.

DCPG
Identifiers
  • 4-phthalic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.161.870 Edit this at Wikidata
Chemical and physical data
FormulaC10H9NO6
Molar mass239.183 g·mol−1
3D model (JSmol)
  • O=C(O)(N)c1cc(c(C(=O)O)cc1)C(=O)O
  • InChI=1S/C10H9NO6/c11-7(10(16)17)4-1-2-5(8(12)13)6(3-4)9(14)15/h1-3,7H,11H2,(H,12,13)(H,14,15)(H,16,17)/t7-/m0/s1 ☒N
  • Key:IJVMOGKBEVRBPP-ZETCQYMHSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

DCPG ((S)-3,4-DCPG) is a drug used in scientific research, which acts as a potent and subtype-selective agonist for the metabotropic glutamate receptor mGluR8. It has anticonvulsant effects in animal studies,[1][2] and has also been investigated as a possible treatment for hyperalgesia.[3]

References

  1. ^ Moldrich RX, Chapman AG, De Sarro G, Meldrum BS (August 2003). "Glutamate metabotropic receptors as targets for drug therapy in epilepsy". European Journal of Pharmacology. 476 (1–2): 3–16. doi:10.1016/s0014-2999(03)02149-6. PMID 12969743.
  2. ^ Folbergrová J, Druga R, Haugvicová R, Mares P, Otáhal J (March 2008). "Anticonvulsant and neuroprotective effect of (S)-3,4-dicarboxyphenylglycine against seizures induced in immature rats by homocysteic acid". Neuropharmacology. 54 (4): 665–75. doi:10.1016/j.neuropharm.2007.11.015. PMID 18191956. S2CID 20697899.
  3. ^ Marabese I, de Novellis V, Palazzo E, Scafuro MA, Vita D, Rossi F, Maione S (February 2007). "Effects of (S)-3,4-DCPG, an mGlu8 receptor agonist, on inflammatory and neuropathic pain in mice". Neuropharmacology. 52 (2): 253–62. doi:10.1016/j.neuropharm.2006.04.006. PMID 17113112. S2CID 25646746.